Ville D Avray

Depression affects a significant portion of the population worldwide, with major depressive episodes (MDE) being a key feature of both Major Depressive Disorder (MDD) and bipolar disorder (BD). The study aims to evaluate the clinical impact and economic aspects of using the EDIT-Bae blood test to improve diagnosis and management of patients with bipolar disorder and major depression. This test may help reduce the average 7-year delay in diagnosing bipolar disorder, which is critical for timely and appropriate treatment. The study involves two groups of patients: one group will have the EDIT-Bae blood test with results available to guide treatment, while the control group will have the test but will not receive the results until the study ends. The EDIT-Bae test uses blood sample analysis and AI-based software interpretation to differentiate between bipolar disorder and major depression. Participants will be followed over six months, with four visits scheduled during this period. Participants will undergo assessments including symptom evaluations and monitoring of depressive symptoms over four months to measure improvement. The study will track health outcomes, diagnosis accuracy, and economic factors related to patient care. Safety and treatment effects will be observed throughout the six-month study duration to understand the benefits and impact of the EDIT-Bae test on managing major depressive episodes.